Connect your AI

Ultragenyx Pharmaceutical RARE Total Assets

Total Assets at other companies

Eli LillyLLY

$116.58B+30.4%

AmgenAMGN

$92.5B+3.5%

Ionis PharmaceuticalsIONS

$3.45B+22.6%

Arrowhead ResearchARWR

$2.27B+44.2%

CRISPR TherapeuticsCRSP

$2.73B+25.8%

ModernaMRNA

$11.49B-9.6%

Other financials

Income statement

Revenue$136.0M-2.2%

Operating income-$169.0M-18.2%

Net income-$185.0M-22.5%

EPS (diluted)-$1.84-17.2%

Balance sheet

Cash & equivalents$175.0M+37.8%

Total debt$36.0M-10.8%

Total equity-$236.0M-264%

Cash flow

Operating cash flow-$197.0M-18.7%

CapEx$1.0M0.0%

Free cash flow-$198.0M-18.6%

Valuation

Market cap$2.83B-39.4%

P/S4.2×-3.7×

Profitability

Gross margin97.2%—

Operating margin-83.8%-3.0pp

Net margin-90.9%-2.1pp

FCF margin-75.1%+10.7pp

Returns & leverage

Return on equity-325.6%+36.9pp

Debt / equity3.7×—

Current ratio2×-0.4×

Where this comes from

Reported directly by Ultragenyx Pharmaceutical in its filing.

Tagged under the XBRL concept us-gaap:Assets.

The official record: Ultragenyx Pharmaceutical’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ultragenyx Pharmaceutical's total assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Ultragenyx Pharmaceutical's total assets?: Ultragenyx Pharmaceutical (RARE) reported total assets of $1.3B in Q1 2026.
How has Ultragenyx Pharmaceutical's total assets changed year-over-year?: Ultragenyx Pharmaceutical's total assets decreased by 1.2% year-over-year, from $1.31B to $1.3B.
What is the long-term trend for Ultragenyx Pharmaceutical's total assets?: Over 5 years (2020 to 2025), Ultragenyx Pharmaceutical's total assets has grown at a -2.7% compound annual growth rate (CAGR), from $1.76B to $1.53B.
What does total assets mean?: The sum of everything the company owns — current assets, property, investments, goodwill, intangibles, and all other assets.